Therefore, inhibition of the IL-17 pathway may provide a new therapeutic approach for patients with moderate to severe psoriasis and ankylosing spondylitis (AS) (Lynde et al., 2014; Chyuan and Chen, 2018). Here, IL17A is linked to psoriasis.